Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.
Colorectal and Lung Tumoroids are Now Available
NEW Blog Post - Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks
Learn More about Discovery's AI-Annotated FFPE Tissues and DiscoverAI Tissue Analysis
NEW Blog Post - Leverage Permeabilized Hepatocytes for Difficult Drug Compounds in Metabolism Studies
Discovery Announces Upcoming Launch of Tumoroids at Precision Med Tri-Con
Colorectal and Lung Tumoroids are Now Available
NEW Blog Post - Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks
Learn More about Discovery's AI-Annotated FFPE Tissues and DiscoverAI Tissue Analysis
NEW Blog Post - Leverage Permeabilized Hepatocytes for Difficult Drug Compounds in Metabolism Studies
Discovery Announces Upcoming Launch of Tumoroids at Precision Med Tri-Con